Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous ADMSC for Premature Ovarian Failure
NCT06132542Phase 1Unknown
- Sponsor
- Mongolian National University of Medical Sciences
- Start
- Jan 2024
- Primary completion
- Oct 2024
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous adipose-derived mesenchymal stromal cells in primary ovarian insufficiency (POI), sponsored by Mongolian National University of Medical Sciences. Primary endpoints: Resumption of menses at 12 months and Improved clinical hormone levels at 12 months. Status: unknown.
02
Drugs
autologous adipose-derived mesenchymal stromal cells
03
Conditions
primary ovarian insufficiency (POI)
Beyond the preview
Go deeper on NCT06132542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06132542.